title: Impact of enteral supplements enriched with omega-3 fatty acids and/or omega-6 fatty acids, arginine and ribonucleic acid compounds on leptin levels and nutritional status in active Crohn's disease treated with prednisolone.
abstract: BACKGROUND
  Patients with Crohn's disease (CD) often develop malnutrition due to disease activity. We aimed to assess the effect of two different enteral supplements of Impact(R) Powder (IP; Novartis, Switzerland) on leptin levels and nutritional status in active CD patients during prednisolone treatment and tapering.
  
  
  METHODS
  Thirty-one CD patients were randomized to IP Extra (group 1) or IP Standard (group 2). Leptin levels, nutritional, clinical and biochemical markers were studied at inclusion, after 5 and after 9 weeks of the study.
  
  
  RESULTS
  Leptin levels, body mass index (BMI) and total cholesterol increased significantly within both groups at week 5 compared to inclusion. Leptin levels correlated with BMI in both groups at inclusion and in group 2 at week 9. In group 1, triglyceride levels remained unchanged, while levels in group 2 increased significantly at week 5 compared to inclusion. Clinical and biochemical markers improved during the study compared to inclusion.
  
  
  CONCLUSIONS
  Increased leptin levels during the study progress were transient, decreasing due to prednisolone withdrawal at the end of the study. Both formulas used as adjuvant therapy to prednisolone treatment were able to improve nutritional status in CD patients.
authors.affiliation: Department of Clinical Biochemistry, Vejle Hospital, Vejle, Denmark. anenie@vgs.vejleamt.dk
authors.forename: Aneta Aleksandra
authors.initials: AA
authors.lastname: Nielsen
authors.forename: Jens Nederby
authors.initials: JN
authors.lastname: Nielsen
authors.forename: Henning
authors.initials: H
authors.lastname: Grønbaek
authors.forename: Martin
authors.initials: M
authors.lastname: Eivindson
authors.forename: Ida
authors.initials: I
authors.lastname: Vind
authors.forename: Pia
authors.initials: P
authors.lastname: Munkholm
authors.forename: Ivan
authors.initials: I
authors.lastname: Brandslund
authors.forename: Henrik
authors.initials: H
authors.lastname: Hey
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D001120:Arginine / Q000008:administration & dosage*; D015992:Body Mass Index; D003424:Crohn Disease / Q000097:blood / Q000628:therapy*; D019587:Dietary Supplements; D004311:Double-Blind Method; D015525:Fatty Acids, Omega-3 / Q000008:administration & dosage*; D043371:Fatty Acids, Omega-6 / Q000008:administration & dosage*; D005260:Female; D005938:Glucocorticoids / Q000627:therapeutic use*; D006801:Humans; D020738:Leptin / Q000097:blood*; D008297:Male; D008875:Middle Aged; D009752:Nutritional Status; D011239:Prednisolone / Q000627:therapeutic use*; D012313:RNA / Q000008:administration & dosage*
chemical_list: D015525:Fatty Acids, Omega-3; D043371:Fatty Acids, Omega-6; D005938:Glucocorticoids; D020738:Leptin; D012313:RNA; D001120:Arginine; D011239:Prednisolone